Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine With or Without Chemoradiotherapy and With or Without Erlotinib in Locally Advanced Pancreatic Adenocarcinoma
2007-001174-81Phase 3Completed
- Sponsor
- GERCOR
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemcitabine and erlotinib in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by GERCOR. Primary endpoints: Overall survival and Progression-free survival. Started May 2007; status: completed.
02
Drugs
gemcitabineerlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2007-001174-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001174-81.